DHC CONTINUS
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
21-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
DIHYDROCODEINE BITARTRATE
Available from:
Napp Pharmaceuticals Limited
Dosage:
60 Milligram
Pharmaceutical form:
Tablets
Authorization date:
1997-03-06
Summary of Product characteristics
License
Part II
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
DHC Continus Prolonged-release Tablets 60 mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Dihydrocodeine Tartrate 60mg
For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Prolonged-release tablets.
White capsule-shaped tablets with 'DHC 60' on one side.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
As an analgesic in the relief of moderate to severe pain.
4.2 Posology and method of adminstration
Adults only
One tablet 12 hourly.
Elderly
Reduced dosage or increased intervals between doses may be required.
Route of Administration
Oral.
4.3 Contraindications
DHC CONTINUS tablets should not be used in patients hypersensitive to the active ingredient or any of the other
constituents of the product or in patients with respiratory depression or obstructive airways disease, paralytic ileus,
head injury, raised intracranial pressure or acute alcoholism. As dihydrocodeine may cause the release of histamine it
should not be given during an attack of asthma. Patients with rare hereditary problems of galactose intolerance, the
Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. DHC CONTINUS tablets
should not be used in children under 12 years
Read the complete document
